Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. March 27, 2018. David Chernoff.

Executive Summary

SetPoint Medical Corp. will begin enrolling 15 rheumatoid arthritis (RA) patients in a study to assess the safety and effectiveness of its unique vagus nerve stimulation system. Check out what David Chernoff, the company's chief medical officer, said about it here.

"We are recruiting patients to evaluate SetPoint's proprietary miniaturized, rechargeable wireless bioelectronic device for RA, building on our body of previous work defining the mechanism of action and proof of concept. This is important because, despite the availability of oral disease-modifying drugs such as methotrexate and multiple targeted biologic agents, only one-third of RA patients on current therapies meet criteria for clinical remission." –David Chernoff, chief medical officer, SetPoint Medical Corp.

Click here for a free trial of Medtech Insight


Related Content

SetPoint Medical Starts Testing Unique Neuromodulation Device In Rheumatoid Arthritis Patients





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts